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Abstract
Background: Bisphenol A (BPA) is a sealant and flux of plastic materials and has been determined to be an
endocrine-disrupting chemical. Prenatal exposure to BPA can lead to substantial adverse effects on fetal growth
and development. This study was conducted to assess BPA concentration in pregnant women and umbilical cord
blood, and to investigate whether maternal BPA exposure affected fetal outcomes including lower birth weight
(LBW), smaller size for gestational age (SGA), and high leptin (HLP) and low adiponectin (LAD) secretion.
Methods: We measured the BPA levels of maternal blood (n = 97) and umbilical cord blood (n = 97) with a high-
performance liquid chromatography/UV detector. The protein secretion of leptin and adiponectin were separately
determined using enzyme-linked immunosorbent assay. A logistic regression was performed to estimate the effects
of maternal exposure to BPA on LBW, SGA, and adverse action of adipokines in newborns.
Results: The geometric means of BPA concentration in maternal blood and fetal cord blood were 2.5 ng/ml and
0.5 ng/ml, respectively. Elevated risks of LBW (OR 2.42, 95% confidence interval (CI) 1.72-3.36), SGA (OR 2.01, 95% CI
1.39-3.01), and adverse action of leptin (OR 1.67, 95% CI 1.12-2.25) and adiponectin (OR 1.25, 95% CI 1.52-3.97) were
observed in male neonates in the highest quartile of maternal BPA exposure.
Conclusions: Elevated prenatal BPA exposure increased the risk of LBW, SGA, and adverse actions of adipokines in
neonates, especially in male infants. These results provide further evidence that maternal exposure is correlated
with adverse birth outcomes.
Background
Bisphenol A (2, 2-bis (4-hydroxyphenol) propane; BPA),
a chemical compound found in plastic products, is
being used increasingly in industrial manufacturing
materials. Numerous reports state that BPA production
was 2, 214, 000 metric tons worldwide per year in 2003
[1], and 3, 200, 000 tons in 2005 [2]. Because BPA is
used to manufacture polycarbonate plastic, epoxy resins
and certain dental sealants [3], humans are frequently
exposed to BPA released from plastics and food cans in
d a i l yl i f e[ 4 ] .T h e r e f o r e ,t h r ough these daily exposures
BPA potentially affects human health.
Previous studies through analyses of BPA in the serum
of pregnant women and in cord blood collected at birth
have indicated that BPA accumulates early in fetuses
[5,6]. Schonfelder et al. [7] stated that BPA levels vary:
from 0.3 to 18.9 ng/ml (median 3.1 ng/ml) in maternal
plasma, from 0.2 to 9.2 ng/ml (median 2.3 ng/ml) in
fetal plasma, and from 1.0 to 104.9 ng/g (median 12.7
ng/ml) in the placenta. BPA can readily cross the pla-
centa [8], and some in vivo experiments have demon-
strated that BPA can cause adverse birth outcomes in
offspring. Pregnant rats were orally administered BPA at
a dose of 10 mg/kg/day resulting in a decreased number
of neonates and decreased survival rate [9]. Female
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exposed to BPA through gavage [10] or osmotic pumps
[11]. Pregnant rats exposed to a low dose of BPA (1
mg/L) in drinking water showed increased adipogenesis
in females at weaning [12].
In utero or neonatal exposure to BPA can alter off-
spring phenotype by stably altering the epigenome, an
effect that can be counteracted by maternal dietary sup-
plements [13]. Male offspring were orally exposed at
lower dosages of BPA (0.05 mg/kg/day), which led to a
significant decrease in weight gain; however, offspring
exposed to BPA treatment at a higher dosage (50 mg/kg/
day) showed higher body weights than the controls [14].
Mechanistically, environmental BPA is a well-known
endocrine-disrupting chemical that binds to estrogen
receptors (ER) a and ERb and results in competition
with estrogen [15], while disrupting the folding, assem-
bly, and shedding of many cellular proteins by targeting
protein disulfide isomerase [16]. BPA can accumulate in
adipose tissue. Fernandez et al. [17] detected an average
3 . 2n gB P A / gf a ta n d8 . 2n gc h l o r i n a t e dB P A / gf a ti n
female adipose tissue. Olea et al. [18] found substantially
higher levels in children. Moreover, BPA present in adi-
pose tissue may alter the release of adiponectin and lep-
tin, which could influence insulin resistance and
increase susceptibility to obesity-associated diseases [19].
Additionally, BPA triggers adipocyte differentiation [20].
The treatment of BPA in mouse 3T3-L1 embryonic
fibroblasts stimulates triglycerol accumulation in adipo-
cytes and hepatocytes, and promotes preadipocytes to
differentiate into mature adipocytes. The 3T3-L1 cells
treated with BPA increase the levels of lipoprotein lipase
and adipocyte-specific fatty acid binding protein (aP2)
mRNAs. Therefore, BPA might mimic estrogen proper-
ties and alter adipokine release, thereby affecting fetal
growth. Thus, this study examined the BPA distribution
in maternal and umbilical cord blood, and its profile of
adipokine protein. We also investigated the effects of
prenatal BPA exposure on fetal birth outcomes includ-
ing fetal development and hormone regulation.
Methods
Study subjects
One hundred and fifty-seven healthy pregnant women
were recruited for this study between January 2006 and
August 2007 at an obstetrics and gynecology clinic in
Hsinchu County, Taiwan. All pregnant women con-
sented to participate in this study, and the bio-sampling
process was approved by the institutional review boards
of National Tsing Hua University. One hundred and
thirty-four subjects (response rate 85.3%) completed a
self-reported questionnaire including physical character-
istics (age, height, weight, occupation, cigarette smoking,
betel quid chewing, and alcohol consumption), dietary
habit, and disease history. Of the 97 mother-newborn
pairs enrolled in the study (72.4%). 37 dropped out
before delivery.
Sample preparation
Maternal blood corresponding to umbilical cord blood
samples were respectively collected in glass heparin
tubes at full-term delivery. Plastics were excluded
throughout the entire analytic procedure to avoid BPA
contamination. Whole blood was centrifuged at 12, 000
rpm for 10 min to separate the plasma and corpuscles,
and stored at -80°C until analysis. To the plasma frac-
tion (500 μl) was added 100 μlo f0 . 0 1Ma m m o n i u m
acetate buffer (pH 4.5; Riedel-de Haen, Seelze, Ger-
many) and 4 ml mixture of n-hexane (HPLC grade;
Echo Chemical, Miaoli, Taiwan) and diethyl ether (70:30
v/v, anhydrous; J.T. Baker, Phillipsburg, NJ). The sam-
ples were mixed for 5 seconds, vortexed for 10 minutes,
immobilized for one minute, and then 8.71 μlo f9 . 1 8 7
M perchloric acid (purity 60-62%; Sigma-Aldrich, St.
Louis, MO) was added. After centrifugation at 3, 000
rpm for 5 minutes, the organic layer was evaporated to
dryness, and reconstituted with 100 μl of mobile phase
(methanol:water 80:20 v/v) for BPA determination by a
reverse-phase high performance liquid chromatography
(HPLC).
Chromatographic system and conditions
The BPA concentrations in plasma were determined
using HPLC chromatography (D-7000) connected to a
UV detector (L-7400) consisting of an autosampler (L-
7200), a pump (L-2130) and a degasys (DG-2410) (Hita-
chi High Technologies America, Pleasanton, CA). HPLC
conditions were as follows: 20 μl injection volume,
Inertsil OctaDecylSilane (ODS)-3V column (5 μm, 250
mm × 4.6 mm; GL Sciences, Torrance, CA) fitted with a
Metaguard Polaris C18 cartridge (5 μm, 4.6 mm; Varian,
Lake Forest, CA) at room temperature, and mobile
phase methanol:water (80:20 v/v) with a flow rate of 0.7
ml/min for 20-minute run time. The eluted peak of
BPA (bis-(4-hydroxyphenyl)-propane, purity > 99%;
Sigma-Aldrich, St. Louis, MO) was detected at 226 nm,
and chromatographic data were analyzed by D-7000
multi-system software version 4.1. Both the initial stan-
dard stock solution, as well as the serial dilutions from
the stock solution in methanol for the HPLC study,
were 0.5 mg/ml in methanol. Linear calibration curves
obtained for BPA ranged from 3.9-250 ng/ml, and the
coefficients of the determinations (r
2) were ≥ 0.995. The
QA/QC materials were prepared from a plasma pool
obtained from multiple anonymous pregnant women
donors in analysis with standard, reagent blank, and
unknown samples. We performed external calibration
using the chromatographic responses of seven standard
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recovery rates of blanks extended from 96-103%. The
relative standard deviation (RSD) among triplicate ana-
lyses were 1.99-7.53%, and the recovery percentage was
96.1% with an RSD of 7.53%. Concentrations below the
limit of detection (LOD) of 0.13 ng/ml [n = 25 (26%)]
were given a value of LOD/√2 for statistical analyses
[21].
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of plasma adiponectin and leptin
protein were determined using Quantikine
® human
immunoassay kits (R&D Systems Inc, Minneapolis, MN)
according to the operation manual. A 96-well polystyr-
ene microplate was coated with mouse monoclonal anti-
bodies individually against adiponectin or leptin globular
domain conjugated to horseradish peroxidase. After
incubation, stabilized hydrogen peroxide and chromogen
tetramethylbenzidine were added, and the optical den-
sity of each well was determined at 450 nm using a
VERSAmax microplate reader (Molecular Devices, Sun-
nyvale, CA). The levels of adiponectin and leptin were
deduced from the absorbance value by extrapolation
from a standard curve generated in parallel. The mini-
mum detectable dose of adiponectin and leptin is typi-
cally less than 0.246 ng/ml and 7.8 pg/ml.
Birth outcome
The newborns were assessed as (a) low birth weight
(LBW) defined as a newborn’s birth weight less than the
10th percentile (< 2, 600 g; n = 20); (b) small for gesta-
tional age (SGA) defined as birth weight less than the
10th percentile, compared with the birth weight distribu-
tion in the same gestation week and gender according to
the data of nationwide newborn’s birth weight percentiles
by gestational age in Taiwan [22]; (c) high leptin (HLP)
defined as the level of leptin more than 90th percentile (>
9.56 ng/ml; n = 25) in cord blood samples; and (d) low
adiponectin (LAD) defined as the level of adiponectin
less than 10th percentile (< 10.32 μg/ml; n = 22).
Statistical analysis
To consider potential confounding variables, a multi-
variable logistic regression was used to model the odds
of adverse outcome variables (LBW, SGA, HLP and
LAD). Previous studies have suggested that maternal
metabolic parameters (HDL, TC, TRG, leptin and adipo-
nectin) are important confounders relevant to birth
weight and adipokine levels [23,24]. Thus, other than
maternal age, BMI, serum BPA concentration, smoking
and socioeconomic status, the maternal metabolic para-
meters, i.e., HDL, TC and TRG were selected as the
independent variables for newborn LBW and SGA out-
comes. Moreover, the maternal concentrations of leptin
and adiponectin were included as potential confounders
for cord blood leptin and adiponectin concentrations.
All statistical analyses were conducted using the SPSS
statistical package (SPSS version 18.0, Chicago, IL). For
continuous exposure variables, a categorical analysis was
performed to compare the difference of study subjects
based on BPA exposure tertile of pregnant women for
testing dose response. We used Spearman correlation
coefficients to assess the correlation of birth outcomes
with categories of the BPA exposure level in pregnant
women. Statistical differences were analyzed using the
Mann-Whitney U test for nominal variables, and Stu-
dent’s t-test or one-way analysis of variance (ANOVA)
for continuous variables. Multiple logistic regression was
used to evaluate the odds ratio of potential effects on
birth outcome attributed to maternal BPA concentra-
tion. All statistical significances were determined with a
two-tailed p < 0.05.
Results
Figure 1A and Figure 1B showed the distributions of
BPA levels respectively in the 97 maternal blood sam-
ples and the 97 fetal umbilical cord blood samples. A
log normal distribution was used to fit both the mater-
nal and fetal BPA concentrations, which display high fit-
ness (r
2 = 0.99). Maternal BPA concentrations were
highly variable (ranging from 0.3 to 29.4 ng/ml),
whereas most fetal BPA levels were < 1 ng/ml (77% of
the samples were 0.3 ng/ml). The geometric means
(GM) of maternal and fetal BPA levels were 2.5 ng/ml
and 0.5 ng/ml, respectively. The GM of maternal BPA
levels was five-fold higher than the fetal umbilical cord
blood.
Table 1 presented demographic characteristics, BPA
levels, and lipid profiles of the 97 pregnant women and
their newborns who participated in this study. The
Figure 1 Distribution of BPA concentrations in (A) maternal
blood samples and (B) fetal umbilical cord blood.
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Page 3 of 10average (± S.D.) age, height, weight and BMI of preg-
nant women were 28.8 ± 3.7 years, 160.9 ± 5.2 cm, 65.3
± 11.2 kg, and 25.2 ± 4.0 kg/m
2. The average values for
serum BPA, adiponectin and leptin were 5.4 ± 6.3 ng/
ml, 6.6 ± 4.7 μg/ml, and 17.9 ± 13.9 ng/ml in pregnant
women, and 1.1 ± 2.2 ng/ml, 21.3 ± 8.2 μg/ml, and 4.6
± 3.5 ng/ml in neonates. The neonates average weight
and gestational age were 3109.6 ± 319.0 g and 38.9 ±
1.1 weeks, respectively. Gender distribution among neo-
nates was 57.7% male and 42.3% female.
Based on the GM of maternal BPA levels, study sub-
jects were divided into high- and low-BPA groups. The
levels of TC and LDL were significantly higher in the
low-BPA group than in the high-BPA group. Addition-
ally, no significant differences in TRG, HDL, adiponectin
and leptin levels were observed between these two














Age (years) 28.8 ± 3.7 29.2 ± 2.9 29.1 ± 3.9 0.43
Height (cm) 160.9 ± 5.2 158.7 ± 4.7 161.9 ± 5.1 0.31
Weight (kg) 65.3 ± 11.2 64.2 ± 11.0 66.7 ± 11.5 0.35
BMI (kg/m
2) 25.2 ± 4.0 25.4 ± 3.6 25.5 ± 4.3 0.85
Smoking 0.69
Yes 12 (13%) 8 (13%) 4 (11%)
No 85 (87%) 54 (87%) 31(89%)
Alcohol 0.78
Yes 7 (7%) 4 (6%) 1 (3%)
No 90 (90%) 58 (94%) 34 (97%)
Socioeconomic status 0.97
High 26 (27%) 16 (26%) 9 (26%)
Medium 24 (25%) 10 (18%) 8 (23%)
Low 47 (48%) 35 (56%) 18 (51%)
TC (mg/dl) 218.9 ± 80.5 187.3 ± 101.2 232 ± 68.4 < 0.05
TRG (mg/dl) 144.4 ± 54.9 142.3 ± 62.4 145.2 ± 52.8 0.59
HDL (mg/dl) 42.9 ± 13.6 47.3 ± 15.0 41.3 ± 13.0 0.36
LDL (mg/dl) 148.5 ± 72.1 115.6 ± 93.7 161.4 ± 59.3 < 0.05
BPA level (ng/ml)
b 5.4 ± 6.3 11.7 ± 6.4 2.1 ± 1.6 < 0.01
Adiponectin protein (μg/ml) 6. 6 ± 4.7 6.4 ± 3.9 6.8 ± 5.2 0.85
Leptin protein (ng/ml) 17.9 ± 13.9 17.6 ± 12.5 18.6 ± 14.9 0.81
Neonates
Birth weight (g) 3109.6 ± 318.9 3067.9 ± 356.4 3212.9 ± 241.2 0.13
Gestation age (weeks) 38.9 ± 1.1 38.9 ± 1.1 38.6 ± 1.2 0.57
Infant sex 0.18
Male 56 (57.7%) 32 (51.6%) 24 (68.6%)
Female 41 (42.37%) 30 (48.4%) 11 (31.4%)
BPA level (ng/ml)
c 1.1 ± 2.2 0.5 ± 0.6 1.4 ± 2.9 0.12
Adiponectin protein (μg/ml) 21.3 ± 8.2 22.1 ± 8.6 21.1 ± 8.2 0.53
Leptin protein (ng/ml) 4.6 ± 3.5 4.6 ± 4.1 4.7 ± 3.3 0.73
Values were presented as mean ± SD.
Abbreviation: TC (total cholesterol), TRG (triglyceride), HDL (high density lipoprotein) and LDL (low density lipoprotein), BMI (body mass index when delivery)
aDivided by geometric mean of maternal BPA level (2.51 ng/ml)
bBPA level was detected in the serum of pregnant women
cBPA level was detected in umbilical cord serum
dp-value from Mann-Whitney U test
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have lower birth weights than those in the low BPA
group (p = 0.13). Some relevant differences between
these two BPA groups were related to the gender of the
infants.
To examine whether BPA exposure in pregnant
women affected fetal BPA exposure and adverse out-
comes, we analyzed the correlation between maternal
BPA level, lipid profile, adipokines, birth weight, and
gestational age (Table 2). The maternal BPA levels
showed a significantly inverse relationship to BMI (r =
-0.48, at 3rd tertile BPA level), TC (r = -0.67, at 2nd ter-
tile BPA level), and LDL (r = -0.61, at 2nd tertile BPA
level), but were positively associated with TRG (r = 0.44,
at 1st tertile BPA level). Moreover, the level of leptin
displayed a significant correlation coefficient with
increased BPA levels (r =0 . 3 9a t1 s tt e r t i l e ,r =0 . 5 0a t
2nd tertile, and r = 0.59 at 3rd tertile BPA level). Con-
versely, maternal BPA exposure had a significant nega-
tive association with neonatal BPA level (r =- 0 . 5 3a t
3rd tertile BPA level) and birth weight (r = -0.24 at total
sample and r = -0.39 at 3rd tertile BPA level).
A ss h o w ni nT a b l e3 ,t h ec r u d eO R ss h o w e dt h a t
maternal BPA exposure was associated with LBW (OR
2.65, 95% CI 1.43-3.47) and SGA (OR 1.93, 95% CI
1.44-2.56) for male neonates but was not significantly
associated with fetal adiponectin and leptin. Further
adjustment for BMI, TC, TRG, HDL, LDL and adipo-
kines attenuated this association, but maternal BPA
exposure was still significantly related to an increased
risk of fetal LBW (OR 2.12, 95% CI 1.05-2.38) and SGA
(OR 1.34, 95% CI 1.13-2.83) in males. Additionally, the
ORs of fetal adverse outcomes and the maternal BPA
level were not observed in female neonates.
The risks of fetal LBW, SGA, LAD, and HLP were
plotted by quartiles based on maternal BPA exposure
levels in Figure 2. Among male infants, the multivariable
adjusted ORs of LBW of the second (OR 2.75, 95% CI
1.52-4.22) and fourth quartile (OR 2.42, 95% CI 1.72-
3.36) of maternal BPA exposure, in contrast to the first
quartile of BPA levels, showed that maternal BPA levels
were significantly associated with an increased risk of
LBW. The adjusted ORs of SGA of the second (OR
0.24, 95% CI 0.17-0.32) and the third quartile (OR 0.44,
95% CI 0.20-0.53) of maternal BPA level were signifi-
cantly decreased, but increased in the fourth quartile
(OR 2.01, 95% CI 0.99-0.62) (Figure 2A). The dose-
response curve at SGA in male infants illustrated a U-
shaped curve, but showed adverse effects at the highest
BPA exposure (4th quartile). Additionally, significantly
increased risks of LAD (OR 1.67, 95% CI 1.12-2.25) and
HLP (OR 3.03, 95% CI 2.09-4.54) were observed for
male neonates at the highest BPA exposure quartile
(Figure 2A). In female neonates, BPA levels in the sec-
ond (OR 2.99, 95% CI 1.47-4.11) and the fourth quartile
(OR 2.17, 95% CI 1.19-3.12) were positively correlated
with an increased risk of SGA presenting a Z-shaped
curve and adverse effects (Figure 2B). Otherwise, the
ORs of LAD were significantly decreased in the second
(OR 0.21, 95% CI 0.10-0.21) and the fourth exposure
quartiles (OR 0.55, 95% CI 0.34-0.56). The ORs of HLP
at the second (OR 0.18, 95% CI 0.12-0.18) and third
Table 2 Correlation between serum BPA levels and characteristics of pregnant women and healthy neonates
Spearman correlation coefficient
Characteristics BPA level (total sample) BPA level (1st tertiles) BPA level (2nd tertiles) BPA level (3rd tertiles)
Pregnant women
Age (years) 0.07 0.01 -0.03 0.12
BMI (kg/m
2) -0.08 -0.01 -0.21 -0.48*
TC (mg/dl) -0.12 0.29 -0.67* 0.29
TRG (mg/dl) 0.20 0.44* -0.52 0.45
HDL (mg/dl) 0.33
# 0.33 -0.21 -0.19
LDL (mg/dl) -0.24 0.19 -0.61
# 0.29
Adiponectin (μg/ml) -0.07 -0.19 -0.02 -0.09
Leptin (ng/ml) 0.11 0.39* 0.50* 0.59*
Newborns
BPA level (ng/ml) -0.05 -0.02 -0.32 -0.53*
Birth weight (g) -0.24* -0.04 -0.24 -0.39
#
Gestation age (weeks) 0.05 0.19 0.09 -0.31
Adiponectin (μg/ml) 0.06 0.19 0.26 0.21
Leptin (ng/ml) -0.08 0.09 0.05 0.04
BPA level divided into three quartiles: Q1 0.3-3.38 (ng/ml), Q2 3.38-7.04 (ng/ml), Q3 > 7.04 (ng/ml)
#p-value < 0.1, *p-value < 0.05
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exposure were significantly decreased, but increased in
the fourth quartile (OR 1.75, 95% CI 1.04-1.85) (Figure
2B). The dose-response curve of HLP in female infants
s h o w e daU - s h a p e ,b u ta d v e r s ee f f e c t sw e r eo b s e r v e da t
the highest exposure quartile of BPA.
Discussion
As BPA recently has been clinically shown in human
and animals to cross the placental barrier, the potential
effects of maternal BPA exposure on prenatal develop-
ment has become a more focal area of research [10,25].
Previous studies have shown that prenatal BPA exposure
in rodents and human is associated with fetal develop-
mental and metabolic adverse effects, for example,
increased birth weight [19,26], reduced gestational age
[27], and disrupted thyroid function [28]. These findings
raise concerns as to the developmental toxicity since the
active BPA dose is considerably lower than the reported
concentrations in the serum of pregnant women in the
U.S. (5.9 ng/ml) and in South Korea (2.7 ng/ml) [29,30].
This study is the first to show the correlation between
maternal BPA exposure and birth outcomes in Taiwan.
We analyzed BPA levels in blood samples obtained from
pregnant women and umbilical cords. The levels of BPA
ranged from 0.3 to 29.4 ng/ml (GM 2.5 ng/ml) and 0.3
to 18.5 ng/ml (GM 1.1 ng/ml) in pregnancy and cord
serum, respectively. A recent study indicated that
approximately 27% of BPA can readily cross a placenta
[8] and that maternal BPA exposure transferred to the
fetus can cause developmental abnormalities and other
adverse health effects in the offspring [10-13]. This
study found a 13% transfer of BPA from maternal blood
to fetal cord blood. The results indicated that fetuses
can be exposed to BPA in utero despite differences in
the placental transfer percentage of BPA in a previous
s t u d y[ 1 0 ] .I nm a l en e o n a t e s ,t h i ss t u d yf o u n das i g n i f i -
cantly negative correlation between fetal birth weight
and maternal BPA level. Additionally, the risks of LBW
and SGA and higher fetal leptin and adiponectin levels
increased with maternal BPA levels in the highest tertile.
That prenatal exposure to BPA seems to cause adverse
effects on fetal growth and development is an important
concern.
The present study revealed several important findings.
First of all, we found a correlation between maternal
BPA exposure and birth outcomes. Prenatal BPA expo-
sure in the highest quartile (> 7.04 ng/ml) was inversely
associated with birth weight, whereas it was not signifi-
cantly correlated at the lowest and second quartiles of
BPA concentrations. Some animal studies supported our
finding that the reduction in weight of both male and
female offspring is associated with prenatal or postwean-
ing exposure to BPA [12,31]. Kim et al. [32] reported
Table 3 Odds ratio of BPA level contributed to low birth weight, small for gestation age, high leptin level, and low
adiponectin level in neonates





All 96 96 3.87 (1.03-4.51) 3.49 (1.07-4.36)
b
Male 69 69 2.65 (1.43-3.47) 2.12 (1.05-2.38)
b
Female 27 27 1.95 (0.51-3.44) 1.81 (0.42-2.09)
b
SGA
All 97 97 2.99 (1.18-5.59) 1.84 (1.55-2.24)
b
Male 51 51 1.93 (1.44-2.56) 1.34 (1.13-2.83)
b
Female 46 46 1.09 (0.31-3.85) 1.02 (0.57-2.09)
b
LAD
All 68 68 1.06 (0.28-2.97) 0.45 (0.07-1.06)
c
Male 38 38 3.00 (0.50-4.95) 1.76 (0.99-3.13)
c
Female 30 30 1.22 (0.02-2.22) 1.17 (0.01-2.13)
c
HLP
All 68 68 1.34 (0.47-3.83) 1.82 (0.35-2.54)
d
Male 38 38 3.09 (0.56-5.17) 3.74 (0.27-6.74)
d
Female 30 30 1.07 (0.23-2.01) 1.14 (0.49-2.29)
d
Abbreviation: LBW (low birth weight), SGA (small for gestation age), LAD (low adiponectin level), HLP (high leptin level)
aCategorical analysis was performed to compare the odds ratio for every birth outcome based on geometric mean of maternal BPA exposure (2.51 ng/ml). The
level of BPA less than LOD was recorded as 1/√2 LOD.
bAdjusted for maternal age, BMI, smoking and socioeconomic status, HDL, TC and TRG
cAdjusted for maternal age, BMI, smoking and socioeconomic status and adiponectin
dAdjusted for maternal age, BMI, smoking and socioeconomic status and leptin
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during the entire gestational period in Sprague-Dawley
rats reduced the weight of the fetuses. Maternal expo-
sure in sheep at BPA levels of 30 to 50 ng/ml during
days 30 to 90 of gestation resulted in low birth weight
in offspring [33]. However, certain studies provided con-
flicting results, reporting an increased weight in off-
spring whose mothers were exposed to BPA during
gestation [26,34,35]. Moreover, mice embryos cultured
at the two-cell stage in 1 nM or 100 μMB P As h o w e d
n on o t e dd i f f e r e n c e si np u pw e i g h ta tb i r t h[ 3 6 ] .H o w -
ever, at the time of weaning on postnatal Day 21, off-
spring from embryos exposed to either dose of BPA
were significantly heavier than the control offspring.
Although this study showed that male fetal birth weight
was negatively correlated with a high level of maternal
BPA exposure, the BPA treatment level of animal mod-
els compared to human exposure should be considered.
Figure 2 Adjusted ORs (95% CIs) of LBW, SGA, HAD and LAP by maternal BPA exposure quartiles. *Statistical significance at 5%.
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have more marked effect on male fetuses than female
fetuses, but they found a significant positive correlation
between maternal serum BPA levels and fetal birth
weight.
Estrogen is known to stimulate cell proliferation for
growth and development. Troisi et al. [37] indicated
that the serum estrogen level of pregnant women is
positively correlated with fetus weight, fetus length, and
head circumference, but with no existing correlation
between the estrogen level of the umbilical cord and
fetus weight. Nagata et al. [38] also found a positive
association between birth weight and maternal serum
estradiol and estriol levels. Aromatase converts testos-
terone to estradiol [39]. Prenatal testosterone treatment
leads to growth retardation and compromised estradiol-
positive feedback, as illustrated by Manikkam et al. [40],
leading to growth retardation and consequently resulting
in low birth weight in sheep. Savabieasfahani et al. [33]
reported low birth weight in offspring because of prena-
tal exposure to BPA and suggested that the effect may
be facilitated through a conversion of testosterone to
estradiol. In the present study, the prenatal BPA expo-
sure in male fetuses with low birth weight suggested a
response to testosterone feedback. Thus, the magnitude
of BPA effect on weight may be influenced by subtle
changes of hormones in utero.
Second, our data demonstrated that pregnant women
exposed to BPA levels greater than 2.51 ng/ml had a
higher risk of giving birth to males with LBW (OR 2.12,
95% CI 1.05-2.38) (Table 3). Moreover, in the male off-
spring, the lower and highest quartiles of BPA levels
conferred a greater risk of LBW than the lowest quartile
of BPA level (Figure 2A). This finding produced a non-
monotonic or a U-shaped dose-response curve consis-
tent with the previous report [41]. Additionally, male
neonates suffered an approximately 34% higher risk of
SGA from a maternal BPA level higher than 2.5 ng/ml
(Table 3). A linear dose-dependent response was noted
at increased quartiles of BPA levels (Figure 2). Conver-
sely, the secretion of leptin and adiponectin was used as
a predictor to assess the potential risk of developing
metabolic syndrome in newborns. Additionally, a higher
relative risk of increased leptin secretion in both male
and female infants corresponding to pregnant women
exposed to the highest quartile BPA level (Figure 2). As
mentioned earlier, our results implied that the effects of
maternal BPA exposure produced a U-shaped dose and
gender dependence on fetal birth outcomes. These
results were consistent with several published studies.
Differential processing of high dose BPA relative to low
dose contributes to the U-shaped, non-monotonic dose-
response curve and gender-difference effects [42,43].
Sex- and dose-dependent differences in weight in
response to early postnatal exposure to diethylstilbestrol,
a synthetic estrogen similar to the BPA structure, have
been reported [35]. Prenatal or neonatal exposure to
BPA was correlated with adverse effects on fetal growth
parameters such as LBW and SGA. Manikkam et al.
[40] reported that exposure to endocrine-disrupting
compounds in utero caused fetal growth retardation in
sheep. Our data suggests that BPA mimics estrogen in
its action, and continued exposure to BPA during gesta-
tion is likely to have an impact on the fetus’ develop-
mental trajectory. In fact, a growing body of evidence, in
addition to our data, had considered LBW and SGA to
be a potential outcome of fetal exposure to BPA or
endocrine-disrupting compounds [33,35].
Thirdly, our data showed that prenatal exposure to
BPA may lead to a potential risk of altering metabolic
features in the fetus such as increasing adverse secretion
of letpin and adiponectin. Phrakonkham et al. [44] sug-
gested that BPA increases gene expression of adipogenic
transcription factors in 3T3-L1 preadipocytes. Perinatal
BPA exposure is associated with the over-expression of
adipocyte hypertrophy and of lipogenic genes in rats
[12]. Moreover, BPA was reported to inhibit adiponectin
secretion from human adipocyte explants in a dose-
dependent manner [45]. An in vivo study suggested that
neonatal estrogenization can influence fetal development
including fetus weight [28]. These studies provided
indirect evidence supporting our observation of BPA
altering the secretion of fetal adipokines. However, more
information about the adipogenic effect of BPA in
fetuses is required for confirmation.
This study has several limitations. First, the level of
plasma BPA was only detected at a single time in con-
nection with delivery. Some imprecision exists because
BPA exposure is variable over time [46]. Thus, this
study assumed that the BPA exposure sources, for
example, living environment, consumption habits, and
exposure routes, were sustained, and that the exposure
level of BPA influencing fetal development and health
would be persistent in maternal plasma, though the
half-life of BPA is relatively short. Second, the statistical
modeling included only maternal age, BMI, and meta-
bolic parameters as control variables to adjust for birth
outcomes (LBW and SGA), but parity, a potential con-
founding factor for birth weight, was not considered.
Additionally, it would be reasonable to concede from
the results of this study that maternal BPA levels were
not significantly correlated with fetal BPA levels. Nishi-
kawa et al. [47] reported that maternal BPA-glucuronide
(BPA-GA) may cross through the placenta and deconju-
gate to BPA in the fetus. Our results suggest that prena-
tal exposure to BPA might influence fetal development
even though we found no significant correlation was
present between maternal and fetal BPA levels due to
Chou et al. Environmental Health 2011, 10:94
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Page 8 of 10the differences in the drug-metabolizing system of
mother and fetus. However, these inferences still require
further confirmation.
Conclusions
The BPA levels detectable in cord blood indicated that
BPA can be transported to the fetus across the placental
barrier. While earlier animal studies have shown a link-
age between BPA exposure and adverse fetal effects, this
study quantified and illustrated a potential risk in
human neonates. However, obtaining more samples
from pregnant women and fetuses under varying expo-
sure levels is necessary to reliably assess the risk posed
by BPA to humans.
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